InVitria Launches Zap-CHO to Enhance CHO Cell Culture PerformanceWith Zap-CHO, customers get the animal free benefit of hydrolysates, the performance of FBS and the consistency of a defined media.
“Zap-CHO is a significant breakthrough in mammalian cell culture systems,” said Dr. Steve Pettit, InVitria’s Director of Cell Culture Development. “With the development of Zap-CHO, InVitria has created a performance enhancing CHO media supplement that is the first animal free supplement capable of replacing fetal bovine serum (FBS) without sacrificing performance and maintaining a well defined media. Since Zap-CHO is a defined and animal component-free product, it is well suited for commercial, chemically-defined and serum- and animal-free cell culture media formulations,” said Dr. Pettit.
Zap-CHO is a next generation media supplement that delivers consistent cell culture performance. Previously, only FBS could deliver equivalent performance, but safety concerns of a fetal bovine component in cell culture media forced many customers away from this component. In the last decade, customers have eliminated FBS in cell culture media only to lose cell culture performance. To regain the lost performance, many began adding hydrolysates to the media. However, hydrolysates introduced significant variability, leading to failed experiments and production failures. Zap-CHO addresses these concerns and provides significant benefits in CHO cell culture, including:
“Our product development team created Zap-CHO to exceed the needs of our customers working in CHO cell culture,” said Scott Deeter, InVitria’s President and CEO. “Our customers have realized exceptional performance results using Zap-CHO. InVitria’s products, like Zap-CHO, are creating a new era for the cell culture manufacturing industry.”
About InVitria (See www.InVitria.com) InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.
For more information about InVitria’s products or to order, please contact InVitria at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call 1-800-916-8311.
|
-
Blog: The Cell Culture Dish
Strategies for Improving Viral Yield in Vaccine Manufacturing
A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More
-
Latest News
InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference
March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more
